• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

OPRD1 Gene Record

  • Summary
  • Interactions
  • Claims
  • OPRD1 4985 Druggable Genome

    Alternate Names:

    4985
    OPIOID RECEPTOR DELTA 1
    OPRD1
    OPRD
    165195
    8153
    ENSG00000116329
    OTTHUMG00000003646
    P41143
    OPRD_HUMAN
    D-OR-1
    Delta-type opioid receptor
    DOR-1
    DELTA-TYPE OPIOID RECEPTOR (DOR-1). [SOURCE:UNIPROT/SWISSPROT;ACC:P41143]
    PA31942
    Opioid receptor delta
    T58992
    DOP
    DOR
    DOR1

    Gene Info:

    Human Readable Name G PROTEIN COUPLED RECEPTOR
    Transmembrane Helix Count 7
    Target Main Class Receptors
    Target Subclass Rhodopsin
    Target Subclass GPCR
    Human Readable Name DRUGGABLE GENOME
    Interpro Acc IPR000276
    Interpro Short Name 7TM_GPCR_Rhodpsn
    Uniprot Evidence 1: Evidence at protein level
    Interpro Name GPCR, rhodopsin-like, 7TM
    Interpro Type Family
    Uniprot Status Swiss-Prot
    Target Class Receptors
    Gene Biotype PROTEIN_CODING
    (8 More Sources)

    Gene Categories: Category Details

    G PROTEIN COUPLED RECEPTOR
    DRUGGABLE GENOME

    Publications:

    Hartvig et al., 1989, Brain and plasma kinetics of the opioid 11C-hydromorphone in two macaque species., Pharmacol. Toxicol.
    Hennies et al., 1988, Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids., Arzneimittelforschung
    Guay, 2007, Use of oral oxymorphone in the elderly., Consult Pharm
    Fang et al., 1997, 7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands., J. Med. Chem.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Jiang et al., 1994, 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone and its corresponding N-cyclopropylmethyl analog, N-cyclopropylmethylnor-5 beta-methyl-14 beta-(p-nitrocinnamoylamino)- 7,8-dihydromorphinone: mu-selective irreversible opioid antagonists., J. Pharmacol. Exp. Ther.
    Vandormael B et al., 2011, Superpotent [Dmt¹] dermorphin tetrapeptides containing the 4-aminotetrahydro-2-benzazepin-3-one scaffold with mixed μ/δ opioid receptor agonistic properties., J Med Chem
    Loghin et al., Influence of glutethimide on rat brain mononucleotides by sub-chronic codeine treatment., J. Cell. Mol. Med.
    Advenier et al., 1993, Antitussive effect of SR 48968, a non-peptide tachykinin NK2 receptor antagonist., Eur. J. Pharmacol.
    Mignat et al., 1995, Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes., Life Sci.
    Ortiz et al., 2005, Probable activation of the opioid receptor-nitric oxide-cyclic GMP-K+ channels pathway by codeine., Pharmacol. Biochem. Behav.
    Karlsson et al., 1990, Airway opioid receptors mediate inhibition of cough and reflex bronchoconstriction in guinea pigs., J. Pharmacol. Exp. Ther.
    Schmidt H et al., 2002, Affinities of dihydrocodeine and its metabolites to opioid receptors., Pharmacol Toxicol
    Ashenhurst JR et al., 2012, Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol., Pharmacol Biochem Behav
    Herz, 1998, Opioid reward mechanisms: a key role in drug abuse?, Can. J. Physiol. Pharmacol.
    Barrios de Tomasi et al., [Opioid antagonists and alcohol consumption]., Rev Neurol
    Herz, 1997, Endogenous opioid systems and alcohol addiction., Psychopharmacology (Berl.)
    Weerts et al., 2008, Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects., Neuropsychopharmacology
    Roy et al., 2005, In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance., J. Neurosci.
    Galeotti et al., 2006, Signaling pathway of morphine induced acute thermal hyperalgesia in mice., Pain
    Dortch-Carnes et al., 2006, Morphine-induced reduction of intraocular pressure and pupil diameter: role of nitric oxide., Pharmacology
    Yamada et al., 2006, Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors., Brain Res.
    Kieffer et al., 2002, Exploring the opioid system by gene knockout., Prog. Neurobiol.
    Asensio et al., 2006, Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by mu-, delta- and kappa-opioid receptor agonists in the rat brain: regulation by chronic morphine and opioid withdrawal., Eur. J. Pharmacol.
    Koch et al., 2006, Role of phospholipase D2 in the agonist-induced and constitutive endocytosis of G-protein coupled receptors., J. Neurochem.
    Thompson et al., 2004, Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors., J. Pharmacol. Exp. Ther.
    Peckham et al., 2006, Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats., J. Pharmacol. Exp. Ther.
    Olson KM et al., 2019, Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids., PLoS One
    Peng Y et al., 2009, Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways., Bioorg Med Chem
    Neil, 1984, Affinities of some common opioid analgesics towards four binding sites in mouse brain., Naunyn Schmiedebergs Arch. Pharmacol.
    Gross et al., 2009, Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion., Anesth. Analg.
    Fang CP et al., 2020, Genetic polymorphisms in the opioid receptor delta 1 (OPRD1) gene are associated with methadone dose in methadone maintenance treatment for heroin dependence., J Hum Genet
    Eap CB et al., 2002, Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence., Clin Pharmacokinet
    Giagnoni et al., 1983, Loperamide: evidence of interaction with mu and delta opioid receptors., Life Sci.
    di Bosco et al., 2008, Binding site of loperamide: automated docking of loperamide in human mu- and delta-opioid receptors., Chem Biol Drug Des
    Barry et al., 2005, Opioids: old drugs for potential new applications., Curr. Pharm. Des.
    Mayberg et al., 1991, Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography., Ann. Neurol.
    De Souza et al., 1988, Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic., J. Pharmacol. Exp. Ther.
    Chen et al., 1993, The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine., Life Sci.
    Fujita et al., 2014, Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers., Biochem. Pharmacol.
    Breslin et al., 2012, Identification of a dual δ OR antagonist/μ OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d)., Bioorg. Med. Chem. Lett.
    Ingman K et al., 2005, Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing., Neuropsychopharmacology
    Paille F et al., 2014, Nalmefene: a new approach to the treatment of alcohol dependence., Subst Abuse Rehabil
    Sahin et al., 2005, The mechanisms of the direct vascular effects of fentanyl on isolated human saphenous veins in vitro., J. Cardiothorac. Vasc. Anesth.
    Poonawala et al., Opioids heal ischemic wounds in the rat., Wound Repair Regen
    Rodrigues et al., 2005, Participation of ATP-sensitive K+ channels in the peripheral antinociceptive effect of fentanyl in rats., Braz. J. Med. Biol. Res.
    Darwish et al., 2006, Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers., Clin Ther
    Hajiha et al., 2009, Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo., J. Physiol. (Lond.)
    Darwish et al., 2005, Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers., Clin Pharmacokinet
    Muriel J et al., 2019, Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients., Basic Clin Pharmacol Toxicol
    Crist RC et al., 2019, Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder., Pharmacogenomics J
    Clarke TK et al., 2014, Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females., Pharmacogenomics J
    Crist RC et al., 2013, An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans., Neuropsychopharmacology
    Lester et al., 2006, Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes., Brain Res.
    Induru et al., Buprenorphine for neuropathic pain--targeting hyperalgesia., Am J Hosp Palliat Care
    Mégarbane et al., 2006, Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation., Toxicol. Appl. Pharmacol.
    Fan et al., 2002, Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain., Brain Res. Bull.
    Picker et al., 1996, Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists., J. Pharmacol. Exp. Ther.
    Fan et al., 2002, Butorphanol dependence and withdrawal decrease hippocampal kappa 2-opioid receptor binding., Brain Res.
    Walsh et al., 2008, Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade., Psychopharmacology (Berl.)
    Narita et al., 1994, Repeated administration of opioids alters characteristics of membrane-bound phorbol ester binding in rat brain., Eur. J. Pharmacol.
    Commiskey et al., 2005, Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors., J. Pharmacol. Sci.
    Wakabayashi et al., 1995, Simultaneous measurement of biogenic amines and their metabolites in rat brain regions after acute administration of and abrupt withdrawal from butorphanol or morphine., Neurochem. Res.
    Cai J et al., 2014, Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity., Bioorg Med Chem
    Kakinohana et al., 2003, Neuraxial morphine may trigger transient motor dysfunction after a noninjurious interval of spinal cord ischemia: a clinical and experimental study., Anesthesiology
    Helm et al., Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification., Pain Physician
    Moncada et al., 2003, Effects of serine/threonine protein phosphatase inhibitors on morphine-induced antinociception in the tail flick test in mice., Eur. J. Pharmacol.
    Breljak et al., Oligopeptide fragments of the enkephalin molecule interfere with hematopoietic cell colony formation., Int J Immunopathol Pharmacol
    Osman et al., 2003, A possible role for an enkephalinergic system in the internal defense mechanism of Biomphalaria alexandrina exposed to Schistosoma mansoni., J Egypt Soc Parasitol
    Chudapongse et al., 2003, Nonspecific effects of the selective kappa-opioid receptor agonist U-50,488H on dopamine uptake and release in PC12 cells., J. Pharmacol. Sci.
    van Dorp et al., 2007, Naloxone treatment in opioid addiction: the risks and benefits., Expert Opin Drug Saf
    Wentland et al., 2009, Syntheses and opioid receptor binding properties of carboxamido-substituted opioids., Bioorg. Med. Chem. Lett.
    Barakat A, 2019, Revisiting Tramadol: A Multi-Modal Agent for Pain Management., CNS Drugs
    Ordóñez Gallego et al., 2007, Oxycodone: a pharmacological and clinical review., Clin Transl Oncol
    Ananthan et al., 2004, Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]., J. Med. Chem.
    Chamberlin et al., 2007, Oral oxymorphone for pain management., Ann Pharmacother
    Freye et al., 1992, The delta receptor is involved in sufentanil-induced respiratory depression--opioid subreceptors mediate different effects., Eur J Anaesthesiol
    Zhu et al., 1996, The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor., FEBS Lett.
  • ELUXADOLINE   OPRD1

    Interaction Score: 3.02

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    25261794 22695132


    Sources:
    DTC TTD

  • HYDROMORPHONE   OPRD1

    Interaction Score: 2.71

    Interaction Types & Directionality:
    partial agonist (activating)
    agonist (activating)

    Interaction Info:
    Trial Name NMED-1077,Exalgo, Jurnista, Dilaudid
    Novel drug target Established target

    PMIDs:
    2478994 2849950 17658959 9301669 11752352 7511163


    Sources:
    TdgClinicalTrial TEND TTD

  • BUTORPHANOL   OPRD1

    Interaction Score: 2.37

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    12127012 8968334 12470863 17909753 7705457 15942128 11752352 8746803


    Sources:
    TdgClinicalTrial TEND TTD

  • CARFENTANIL   OPRD1

    Interaction Score: 2.26

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    15853689 1656846


    Sources:
    TTD

  • NALTREXONE   OPRD1

    Interaction Score: 2.07

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist
    Direct Interaction yes
    Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

    PMIDs:
    22954510 9673788 17661275 9040115 17487229 11752352 15788780


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • CODEINE   OPRD1

    Interaction Score: 1.89

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    12067475 8119316 7885194 16386786 11752352 2156065 12420793


    Sources:
    TdgClinicalTrial TEND TTD

  • HYDROCODONE   OPRD1

    Interaction Score: 1.81

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name ZX002, hydrocodone bitartrate
    Novel drug target Established target
    Trial Name PTI-701

    PMIDs:
    14600248 11752352 16291875 31170174


    Sources:
    TdgClinicalTrial TEND

  • ADL-5747   OPRD1

    Interaction Score: 1.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • NALOXONE   OPRD1

    Interaction Score: 1.51

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name REN-213
    Novel drug target Established target

    PMIDs:
    24613457 12657847 18354714 12650833 12749773 14708857 14646257 17367258


    Sources:
    DTC TdgClinicalTrial TEND

  • NALMEFENE   OPRD1

    Interaction Score: 1.51

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name nalmefene, CPH-101
    Novel drug target Established target

    PMIDs:
    15956985 25187751


    Sources:
    TdgClinicalTrial

  • ADL-5747   OPRD1

    Interaction Score: 1.51

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name ADL5747
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • CHEMBL409225   OPRD1

    Interaction Score: 1.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21978284


    Sources:
    DTC

  • BUPRENORPHINE   OPRD1

    Interaction Score: 1.36

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name V1003
    Novel drug target Established target
    Trial Name ALKS 5461

    PMIDs:
    30549211 30368523 24126707 23612435 16443205 19666890 16169027


    Sources:
    TdgClinicalTrial PharmGKB

  • NALBUPHINE   OPRD1

    Interaction Score: 1.26

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name nalbuphine hydrochloride, PW-4142
    Novel drug target Established target
    Trial Name REN-213

    PMIDs:
    2826773 8093631 11752352


    Sources:
    TdgClinicalTrial TEND

  • OXYMORPHONE   OPRD1

    Interaction Score: 1.13

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name oxymorphone hydrochloride, EN3202,Opana, Opana ER
    Novel drug target Established target

    PMIDs:
    14998329 17595308


    Sources:
    TdgClinicalTrial

  • PROPOXYPHENE   OPRD1

    Interaction Score: 1.13

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    6151117


    Sources:
    TdgClinicalTrial TEND

  • OXYCODONE   OPRD1

    Interaction Score: 1.01

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name COL-003, sustained release oxycodone
    Novel drug target Established target
    Trial Name COL-172, extended-release oxycodone

    PMIDs:
    17525040 11752352


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • SNC-80   OPRD1

    Interaction Score: 1.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19646882


    Sources:
    DTC

  • CHEMBL300662   OPRD1

    Interaction Score: 0.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CHEMBL13786   OPRD1

    Interaction Score: 0.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • SUFENTANIL   OPRD1

    Interaction Score: 0.65

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name sufentanil transdermal patch,Transdur-sufentanil
    Novel drug target Established target
    Trial Name sufentanil,Chronogesic

    PMIDs:
    1330549 8612823


    Sources:
    TdgClinicalTrial

  • FENTANYL   OPRD1

    Interaction Score: 0.6

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name transmucosal fentanyl,Actiq
    Trial Name fentanyl transdermal system,Duragesic, Ionsys
    Trial Name fentanyl sublingual spray

    PMIDs:
    15868528 15828941 15665994 16861092 19403616 16372825 30549211


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • LOPERAMIDE   OPRD1

    Interaction Score: 0.6

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    6319884 18284554 11752352


    Sources:
    TTD

  • NALTREXONE HYDROCHLORIDE   OPRD1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • NALBUPHINE HYDROCHLORIDE   OPRD1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Opioid receptors; mu/kappa/delta agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CODEINE POLISTIREX   OPRD1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Opioid receptors; mu/kappa/delta agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • HYDROCODONE POLISTIREX   OPRD1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Opioid receptors; mu/kappa/delta agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • HYDROCODONE BITARTRATE   OPRD1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Opioid receptors; mu/kappa/delta agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CODEINE SULFATE   OPRD1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Opioid receptors; mu/kappa/delta agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CODEINE PHOSPHATE   OPRD1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Opioid receptors; mu/kappa/delta agonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • NALMEFENE HYDROCHLORIDE   OPRD1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ODELEPRAN   OPRD1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • OXYMORPHONE HYDROCHLORIDE   OPRD1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Opioid receptors; mu/kappa/delta agonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BENZHYDROCODONE HYDROCHLORIDE   OPRD1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name KP201 (prodrug of hydrocodone)
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • AXOMADOL   OPRD1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Delta opioid receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • MORPHINE   OPRD1

    Interaction Score: 0.44

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT
    Novel drug target Established target
    Trial Name intranasal morphine,Rylomine

    PMIDs:
    16650582 16534251 16530171 12015197 16678156 11752352 16539674


    Sources:
    TdgClinicalTrial TEND

  • CEBRANOPADOL   OPRD1

    Interaction Score: 0.38

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Opioid receptors; mu/kappa/delta agonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • NALOXONE HYDROCHLORIDE   OPRD1

    Interaction Score: 0.38

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TRAMADOL   OPRD1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    19027293 30549211 31004280


    Sources:
    PharmGKB

  • METHADONE   OPRD1

    Interaction Score: 0.22

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    19843777 31907389 12405865


    Sources:
    PharmGKB

  • COCAINE   OPRD1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • Ensembl: ENSG00000116329

    • Version: 101_38

    Alternate Names:
    OPRD1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000116329

    • Version: 26-July-2011

    Alternate Names:
    OPRD1 Display Id
    ENSG00000116329 Ensembl Gene Id
    DELTA-TYPE OPIOID RECEPTOR (DOR-1). [SOURCE:UNIPROT/SWISSPROT;ACC:P41143] Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TEND: P41143

    • Version: 01-August-2011

    Alternate Names:
    P41143 Uniprot Accession
    OPRD_HUMAN Uniprot Id
    4985 Entrez Gene Id

    Gene Info:
    Transmembrane Helix Count 7
    Target Main Class Receptors
    Target Subclass Rhodopsin

    Publications:

  • HopkinsGroom: P41143

    • Version: 11-September-2012

    Alternate Names:
    DELTA-TYPE OPIOID RECEPTOR Uniprot Protein Name
    OPRD1 Uniprot Gene Name
    P41143 Uniprot Accession

    Gene Info:
    Human Readable Name DRUGGABLE GENOME
    Interpro Acc IPR000276
    Interpro Short Name 7TM_GPCR_Rhodpsn

    Gene Categories:
    G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME

    Publications:

  • TdgClinicalTrial: P41143

    • Version: January-2014

    Alternate Names:
    OPRD1 Gene Symbol

    Gene Info:
    Target Subclass Rhodopsin
    Target Class Receptors
    Target Subclass GPCR

    Publications:

  • PharmGKB: OPRD1

    • Version: 18-August-2020

    Alternate Names:
    PA31942 PharmGKB ID

    Gene Info:

    Publications:
    Fang CP et al., 2020, Genetic polymorphisms in the opioid receptor delta 1 (OPRD1) gene are associated with methadone dose in methadone maintenance treatment for heroin dependence., J Hum Genet
    Muriel J et al., 2019, Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients., Basic Clin Pharmacol Toxicol
    Crist RC et al., 2013, An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans., Neuropsychopharmacology

  • TTD: Opioid receptor delta

    • Version: 2020.06.01

    Alternate Names:
    OPRD1 TTD Gene Abbreviation
    T58992 TTD Target ID

    Gene Info:

    Publications:
    Al-Hasani R et al., 2011, Molecular mechanisms of opioid receptor-dependent signaling and behavior., Anesthesiology

  • DTC: OPRD1

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Vandormael B et al., 2011, Superpotent [Dmt¹] dermorphin tetrapeptides containing the 4-aminotetrahydro-2-benzazepin-3-one scaffold with mixed μ/δ opioid receptor agonistic properties., J Med Chem
    Cai J et al., 2014, Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity., Bioorg Med Chem
    Breslin et al., 2012, Identification of a dual δ OR antagonist/μ OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d)., Bioorg. Med. Chem. Lett.

  • ChemblInteractions: OPRD

    • Version: chembl_23

    Alternate Names:
    OPRD GENE_SYMBOL
    OPRD1 GENE_SYMBOL
    Delta-type opioid receptor UNIPROT

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000116329

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000116329 Gene Symbol
    OPRD1 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • GO: OPRD1

    • Version: 01-February-2022

    Alternate Names:
    OPRD GO Gene Synonym

    Gene Info:

    Gene Categories:
    G PROTEIN COUPLED RECEPTOR

    Publications:

  • dGene: OPRD1

    • Version: 27-Jun-2013

    Alternate Names:
    4985 Gene ID
    OPRD dGene Synonym

    Gene Info:

    Gene Categories:
    G PROTEIN COUPLED RECEPTOR

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21